Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.
Merz V, Maines F, Marcucci S, Sartori C, Frisinghelli M, Trentin C, Kadrija D, Carbone FG, Michielan A, Gabbrielli A, Melisi D, Barbareschi M, Brolese A, Caffo O. Merz V, et al. Among authors: frisinghelli m. J Cancer Res Clin Oncol. 2024 Jul 11;150(7):347. doi: 10.1007/s00432-024-05841-z. J Cancer Res Clin Oncol. 2024. PMID: 38990367 Free PMC article.
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Merz V, et al. Among authors: frisinghelli m. Front Surg. 2022 May 4;9:866173. doi: 10.3389/fsurg.2022.866173. eCollection 2022. Front Surg. 2022. PMID: 35599791 Free PMC article. Review.
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Caffo O, Pappagallo G, Brugnara S, Caldara A, di Pasquale MC, Ferro A, Frisinghelli M, Murgia V, Russo LM, Soini B, Valduga F, Veccia A, Galligioni E. Caffo O, et al. Among authors: frisinghelli m. Urology. 2012 Mar;79(3):644-9. doi: 10.1016/j.urology.2011.11.043. Urology. 2012. PMID: 22386418
Clinical results of active scanning proton therapy for primary liver tumors.
Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, Morganti AG, Pravadelli C, Avancini I, Rozzanigo U, Mattiuzzi A, Frisinghelli M, Pertile R, Ciarleglio FA, Vitale A, Schwarz M, Amichetti M. Dionisi F, et al. Among authors: frisinghelli m. Tumori. 2021 Feb;107(1):71-79. doi: 10.1177/0300891620937809. Epub 2020 Jul 10. Tumori. 2021. PMID: 32648818
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.
Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group. Ménard S, et al. Among authors: frisinghelli m. Ann Oncol. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9. Ann Oncol. 2008. PMID: 18544559 Free article.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
16 results